30th Aug 2018 08:23
LONDON (Alliance News) - AstraZeneca PLC on Thursday said the European Commission has approved its Bydureon BCise device for type-2 diabetes as a new formulation.
Bydureon BCise has been approved within the market authorisation for Bydureon, Astra's extended release form of exenatide. The device is a single-dose pre-filled pen and can be used in combination with other medications to help type-2 diabetics control their blood sugar levels.
The device is targeted at those patients whose blood sugar is not sufficiently controlled by other medications or lifestyle changes.
Shares in AstraZeneca were down 0.6% at 5,855.00 pence on Thursday morning.
Related Shares:
Astrazeneca